# US 8,568,995 B2 · Methods for assessing modified LDL immune complexes in subjects having or at risk of coronary artery disease > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,568,995 B2 - Document ID: US8568995B2 - Status: Granted - Kind: B2 - Application number: 12/885,020 - Filed: 2010-09-17 - Published: 2011-05-26 - Granted: 2013-10-29 - Earliest claimed: 2009-09-18 - Assignees: MUSC Foundation for Research Development; Department of Veterans Affairs - Applicants: Maria F. Lopes-Virella; Gabriel T. Virella - Inventors: Maria F. Lopes-Virella; Gabriel T. Virella - Web page: https://patentgrep.com/patent/US8568995B2 ## CPC - G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)} - G01N 33/6893: {related to diseases not provided for elsewhere} - G01N 2440/38: addition of carbohydrates, e.g. glycosylation, glycation - G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism - G01N 2800/324: Coronary artery diseases, e.g. angina pectoris, myocardial infarction - G01N 2800/50: Determining the risk of developing a disease - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The present invention relates to the analysis of modified LDL in the context of immune complexes. In particular, ox-LDL and AGE-LDL are shown to predict the development of coronary artery disease and other micro- and macrovascular disorders, particularly in the context of diabetes. ## Claims ### Claim 1 A method of predicting risk of coronary artery disease (CAD) in a subject comprising: (a) providing a modified low density lipoprotein-immune complex (mod-LDL-IC)-containing sample from said subject; (b) measuring oxidized-LDL immune complexes (ox-LDL-IC) and/or advanced glycation endproduct-LDL immune complexes (AGE-LDL-IC) in said sample; (c) comparing the amount of ox-LDL-IC and/or AGE-LDL-IC in said sample to a normal standard; and (d) predicting that said subject is at risk of developing CAD where an elevated amount of ox-LDL-IC and/or AGE-LDL-IC as compared to said standard is observed, or predicting that said subject is at not risk of developing CAD based where an elevated amount of ox-LDL-IC and/or AGE-LDL-IC as compared to said standard is not observed. ### Claim 2 (depends on 1) The method of claim 1, wherein said mod-LDL-IC-containing sample is serum or plasma. ### Claim 3 (depends on 1) The method of claim 1, wherein measuring comprises (i) isolating mod-LDL-IC, (ii) separating mod-LDL from antibodies in said mod-LDL-IC, and (iii) determining ox-LDL and/or AGE-LDL from said mod-LDL-IC levels. ### Claim 4 (depends on 3) The method of claim 3, wherein isolating mod-LDL-IC comprises precipitation. ### Claim 5 (depends on 4) The method of claim 4, wherein separating comprises affinity chromatography of precipitated mod-LDL-IC followed by selective elution of mod-LDL. ### Claim 6 (depends on 3) The method of claim 3, wherein determining comprises capture immunoassay, competitive immunoassay, gas chromatography, mass spectrometry, gel electrophoresis or column chromatography. ### Claim 7 (depends on 1) The method of claim 1, wherein said subject has a family history of CAD. ### Claim 8 (depends on 1) The method of claim 1, wherein said subject exhibits elevated ox-LDL levels. ### Claim 9 (depends on 1) The method of claim 1, wherein said subject exhibits elevated AGE-LDL levels. ### Claim 10 (depends on 1) The method of claim 1, wherein said subject exhibits elevated ox-LDL levels and elevated AGE-LDL levels. ### Claim 11 (depends on 1) The method of claim 1, wherein said subject does not exhibit elevated ox-LDL levels or elevated AGE-LDL levels. ### Claim 12 (depends on 1) The method of claim 1, wherein said subject is male. ### Claim 13 (depends on 1) The method of claim 1, wherein said subject is female. ### Claim 14 (depends on 1) The method of claim 1, wherein said subject is 5 years of age or less. ### Claim 15 (depends on 1) The method of claim 1, wherein said subject is 10 years of age or less. ### Claim 16 (depends on 1) The method of claim 1, wherein said subject is 15 years of age or less. ### Claim 17 (depends on 1) The method of claim 1, wherein said subject is 20 years of age or less. ### Claim 18 (depends on 1) The method of claim 1, wherein said CAD is secondary to type 1 diabetes. ### Claim 19 (depends on 1) The method of claim 1, wherein said CAD is secondary to type 2 diabetes. ### Claim 20 (depends on 1) The method of claim 1, wherein said CAD is secondary to a chronic autoimmune disorder.